Search
RG2417
go.drugbank.com/drugs/DB05055InvestigationalThe rationale for uridine therapy in neuropsychiatric disorders is supported by preclinical and clinical research. … RG2417 is a proprietary formulation of uridine, a biological compound essential for the synthesis of DNA and RNA, the basic hereditary material found in all cells, and numerous other factors essential
Adipiplon
go.drugbank.com/drugs/DB06579InvestigationalAdipiplon is an nonbenzodiazepine anxiolytic developed by Neurogen Corporation. It is known by the standardized identifier NG2-73.
H3B-8800
go.drugbank.com/drugs/DB14017InvestigationalH3B-8800 was granted orphan drug status by the FDA in August 2017 and is in clinical trials for the treatment of acute myelogenous leukemia and chronic myelomonocytic leukemia [L2551]. … H3B-8800 is a novel spliceosome inhibitor developed by H3 Biomedicine [L2551].
Bordetella pertussis toxoid antigen (glutaraldehyde inactivated)
go.drugbank.com/drugs/DB10787ApprovedInvestigationalMixtures: INACTIVATED), BORDETELLA PERTUSSIS TOXOID ANTIGEN (GLUTARALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS FILAMENTOUS HEMAGGLUTININ ANTIGEN (FORMALDEHYDE INACTIVATED), BORDETELLA PERTUSSIS PERTACTIN ANTIGEN, andMEM 1414
go.drugbank.com/drugs/DB05888ExperimentalMEM 1414 works by blocking phosphodiesterase, an enzyme that breaks down an important brain chemical, cyclic AMP. It appears to work in the area of the brain where new memories are formed.
Patupilone
go.drugbank.com/drugs/DB03010InvestigationalEpothilone B is a 16-membered macrolide that mimics the biological effects of taxol.
Octopamine
go.drugbank.com/drugs/DB13251ExperimentalIt has been used as a nootropic, and therefore it and all of its enantiomer are prohibited by the World Anti-doping Agency (WADA) as of 2014.
Categories: Adrenergic and Dopaminergic AgentsLemuteporfin
go.drugbank.com/drugs/DB04980InvestigationalLemuteporfin, under development by QLT Incorporated, is a benzoporphyrin-derived chlorin-like photosensitizer. It is intended for the treatment of beign prostatic hyperplasia.
Neratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer.
Categories: Antineoplastic and Immunomodulating Agents